drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00519 | DB01234 | 1,638 | 1,220 | [
"DDInter1843",
"DDInter513"
] | Trandolapril | Dexamethasone | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1638,
24,
1220
]
],
[
[
1638,
24,
870
],
[
870,
1,
1220
]
],
[
[
1638,
24,
175
],
[
175,
40,
1220
]
],
[
[
1638,
63,
251
],
[
251,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles... |
DB00535 | DB06723 | 1,145 | 115 | [
"DDInter315",
"DDInter58"
] | Cefdinir | Aluminum hydroxide | Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat ... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1145,
24,
115
]
],
[
[
1145,
21,
28882
],
[
28882,
60,
115
]
],
[
[
1145,
1,
1462
],
[
1462,
24,
115
]
],
[
[
1145,
24,
428
],
[
428,
... | [
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Cefdinir",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increa... | Cefdinir (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Cefdinir (Compound) resembles Cefditoren (Compound) and Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxid... |
DB01229 | DB13007 | 973 | 1,060 | [
"DDInter1377",
"DDInter642"
] | Paclitaxel | Enfortumab vedotin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
973,
24,
1060
]
],
[
[
973,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
973,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
973,
63,
14
],
[
14,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and ... |
DB06228 | DB11986 | 792 | 484 | [
"DDInter1609",
"DDInter648"
] | Rivaroxaban | Entrectinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
792,
24,
484
]
],
[
[
792,
24,
466
],
[
466,
62,
484
]
],
[
[
792,
63,
222
],
[
222,
23,
484
]
],
[
[
792,
64,
998
],
[
998,
24,... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and ... |
DB00106 | DB06589 | 618 | 1,250 | [
"DDInter4",
"DDInter1400"
] | Abarelix | Pazopanib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
618,
24,
1250
]
],
[
[
618,
23,
1247
],
[
1247,
23,
1250
]
],
[
[
618,
24,
479
],
[
479,
23,
1250
]
],
[
[
618,
24,
1630
],
[
1630,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Done... |
DB01409 | DB08897 | 1,415 | 1,429 | [
"DDInter1815",
"DDInter22"
] | Tiotropium | Aclidinium | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1415,
35,
1429
]
],
[
[
1415,
63,
352
],
[
352,
24,
1429
]
],
[
[
1415,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
1415,
6,
4304
],
[
4304,... | [
[
[
"Tiotropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Tiotropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Tiotropium (Compound) resembles Aclidinium (Compound) and
Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Tiotropium may cause a moderate interaction that could exa... |
DB01023 | DB11093 | 409 | 636 | [
"DDInter716",
"DDInter273"
] | Felodipine | Calcium citrate | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
409,
24,
636
]
],
[
[
409,
1,
376
],
[
376,
24,
636
]
],
[
[
409,
40,
1428
],
[
1428,
24,
636
]
],
[
[
409,
1,
376
],
[
376,
40,... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Felodipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a mo... | Felodipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Felodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Calciu... |
DB00741 | DB08886 | 167 | 637 | [
"DDInter885",
"DDInter126"
] | Hydrocortisone | Asparaginase Erwinia chrysanthemi | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
167,
24,
637
]
],
[
[
167,
24,
392
],
[
392,
24,
637
]
],
[
[
167,
24,
1385
],
[
1385,
63,
637
]
],
[
[
167,
63,
1274
],
[
1274,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when tak... |
DB06273 | DB15091 | 980 | 676 | [
"DDInter1824",
"DDInter1901"
] | Tocilizumab | Upadacitinib | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
980,
25,
676
]
],
[
[
980,
23,
1193
],
[
1193,
23,
676
]
],
[
[
980,
62,
1461
],
[
1461,
23,
676
]
],
[
[
980,
24,
1430
],
[
1430,
... | [
[
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc... | Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and V... |
DB00563 | DB00685 | 663 | 1,299 | [
"DDInter1174",
"DDInter1887"
] | Methotrexate | Trovafloxacin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Moderate | 1 | [
[
[
663,
24,
1299
]
],
[
[
663,
24,
872
],
[
872,
40,
1299
]
],
[
[
663,
63,
1467
],
[
1467,
40,
1299
]
],
[
[
663,
18,
3199
],
[
3199,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Trovafloxacin (... |
DB01211 | DB14723 | 609 | 159 | [
"DDInter393",
"DDInter1026"
] | Clarithromycin | Larotrectinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
609,
25,
159
]
],
[
[
609,
62,
222
],
[
222,
23,
159
]
],
[
[
609,
23,
907
],
[
907,
23,
159
]
],
[
[
609,
64,
318
],
[
318,
23,... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Doravirine and... |
DB01177 | DB11757 | 77 | 960 | [
"DDInter904",
"DDInter994"
] | Idarubicin | Istradefylline | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
77,
24,
960
]
],
[
[
77,
63,
134
],
[
134,
24,
960
]
],
[
[
77,
24,
1374
],
[
1374,
24,
960
]
],
[
[
77,
24,
971
],
[
971,
63,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and... |
DB01087 | DB09330 | 1,520 | 985 | [
"DDInter1520",
"DDInter1352"
] | Primaquine | Osimertinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1520,
25,
985
]
],
[
[
1520,
62,
1247
],
[
1247,
23,
985
]
],
[
[
1520,
63,
480
],
[
480,
24,
985
]
],
[
[
1520,
24,
657
],
[
657,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfa... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol a... |
DB01278 | DB01403 | 1,021 | 9 | [
"DDInter1506",
"DDInter1175"
] | Pramlintide | Methotrimeprazine | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1021,
24,
9
]
],
[
[
1021,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1021,
63,
401
],
[
401,
24,
9
]
],
[
[
1021,
63,
1630
],
[
1630,
1... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate... |
DB00031 | DB08896 | 20 | 292 | [
"DDInter1764",
"DDInter1576"
] | Tenecteplase | Regorafenib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
20,
25,
292
]
],
[
[
20,
24,
643
],
[
643,
24,
292
]
],
[
[
20,
24,
41
],
[
41,
63,
292
]
],
[
[
20,
25,
553
],
[
553,
25,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"D... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomiln... |
DB04948 | DB06699 | 1,084 | 774 | [
"DDInter1083",
"DDInter493"
] | Lofexidine | Degarelix | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1084,
24,
774
]
],
[
[
1084,
63,
521
],
[
521,
1,
774
]
],
[
[
1084,
62,
112
],
[
112,
23,
774
]
],
[
[
1084,
63,
888
],
[
888,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can lim... |
DB00757 | DB01263 | 1,166 | 859 | [
"DDInter581",
"DDInter1494"
] | Dolasetron | Posaconazole | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
1166,
25,
859
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1166,
21,
29892
],
[
29892,
60,
859
]
],
[
[
1166,
23,
112
],
[
112,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Posac... | Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Dolasetron (Compound) causes Prothrombin level increased (Side Effect) and Prothrombin level increased (Side Effect) is caused by Posaconazole (Compound)
Dolasetron may cause a minor interaction that can limit clinical effec... |
DB08865 | DB09104 | 1,593 | 286 | [
"DDInter448",
"DDInter1118"
] | Crizotinib | Magnesium hydroxide | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1593,
24,
286
]
],
[
[
1593,
63,
1482
],
[
1482,
23,
286
]
],
[
[
1593,
64,
820
],
[
820,
23,
286
]
],
[
[
1593,
24,
1468
],
[
1468,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Crizotinib may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may... |
DB01001 | DB13074 | 688 | 877 | [
"DDInter1632",
"DDInter1110"
] | Salbutamol | Macimorelin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
688,
25,
877
]
],
[
[
688,
62,
112
],
[
112,
23,
877
]
],
[
[
688,
23,
1247
],
[
1247,
23,
877
]
],
[
[
688,
24,
673
],
[
673,
2... | [
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and... |
DB01100 | DB09268 | 1,568 | 1,662 | [
"DDInter1470",
"DDInter1464"
] | Pimozide | Picosulfuric acid | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Major | 2 | [
[
[
1568,
25,
1662
]
],
[
[
1568,
25,
484
],
[
484,
63,
1662
]
],
[
[
1568,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1568,
64,
597
],
[
597,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"... | Pimozide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Pimozide may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a mode... |
DB08895 | DB12825 | 976 | 1,375 | [
"DDInter1825",
"DDInter1032"
] | Tofacitinib | Lefamulin | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
976,
24,
1375
]
],
[
[
976,
24,
159
],
[
159,
63,
1375
]
],
[
[
976,
64,
1532
],
[
1532,
24,
1375
]
],
[
[
976,
24,
98
],
[
98,
... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Tofacitinib may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may... |
DB01041 | DB01076 | 770 | 700 | [
"DDInter1789",
"DDInter133"
] | Thalidomide | Atorvastatin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
770,
24,
700
]
],
[
[
770,
24,
788
],
[
788,
1,
700
]
],
[
[
770,
6,
10215
],
[
10215,
45,
700
]
],
[
[
770,
7,
7669
],
[
7669,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Thalidomide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Atorvastatin (Compound)
Thalidomide (Compound) upregulates DDIT4 (Gene) and DD... |
DB01403 | DB11110 | 9 | 603 | [
"DDInter1175",
"DDInter1115"
] | Methotrimeprazine | Magnesium citrate | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
9,
24,
603
]
],
[
[
9,
64,
57
],
[
57,
24,
603
]
],
[
[
9,
24,
1616
],
[
1616,
24,
603
]
],
[
[
9,
63,
1151
],
[
1151,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Methotrimeprazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
... | Methotrimeprazine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with His... |
DB00916 | DB00927 | 112 | 1,559 | [
"DDInter1202",
"DDInter712"
] | Metronidazole | Famotidine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Minor | 0 | [
[
[
112,
23,
1559
]
],
[
[
112,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
112,
23,
1247
],
[
1247,
62,
1559
]
],
[
[
112,
24,
1468
],
[
1468... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is ca... | Metronidazole (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken ... |
DB00417 | DB00563 | 1,667 | 663 | [
"DDInter1445",
"DDInter1174"
] | Phenoxymethylpenicillin | Methotrexate | Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or [benzylpenicillin]. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, s... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Major | 2 | [
[
[
1667,
25,
663
]
],
[
[
1667,
18,
4729
],
[
4729,
57,
663
]
],
[
[
1667,
21,
28681
],
[
28681,
60,
663
]
],
[
[
1667,
24,
126
],
[
126,... | [
[
[
"Phenoxymethylpenicillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Phenoxymethylpenicillin",
"{u} (Compound) downregulates {v} (Gene)",
"EBNA1BP2"
],
[
"EBNA1BP2",
"{u} (Gene) is ... | Phenoxymethylpenicillin (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Methotrexate (Compound)
Phenoxymethylpenicillin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Phenoxymethylpenicillin may cause a moderate i... |
DB01229 | DB01320 | 973 | 651 | [
"DDInter1378",
"DDInter783"
] | Paclitaxel (protein-bound) | Fosphenytoin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
973,
24,
651
]
],
[
[
973,
62,
307
],
[
307,
1,
651
]
],
[
[
973,
63,
362
],
[
362,
1,
651
]
],
[
[
973,
6,
6017
],
[
6017,
45,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Paclitaxel may cause a moderate interaction that could exa... |
DB00420 | DB00981 | 508 | 1,528 | [
"DDInter1532",
"DDInter1462"
] | Promazine | Physostigmine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
508,
24,
1528
]
],
[
[
508,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
508,
24,
543
],
[
543,
24,
1528
]
],
[
[
508,
1,
104
],
[
104,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lop... |
DB00295 | DB00801 | 475 | 1,563 | [
"DDInter1244",
"DDInter850"
] | Morphine | Halazepam | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Major | 2 | [
[
[
475,
25,
1563
]
],
[
[
475,
25,
686
],
[
686,
1,
1563
]
],
[
[
475,
25,
902
],
[
902,
40,
1563
]
],
[
[
475,
64,
1174
],
[
1174,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halazepam"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxazepam"
],
[
"Oxazepam",
"{u} (Compound)... | Morphine may lead to a major life threatening interaction when taken with Oxazepam and Oxazepam (Compound) resembles Halazepam (Compound)
Morphine may lead to a major life threatening interaction when taken with Clobazam and Clobazam (Compound) resembles Halazepam (Compound)
Morphine may lead to a major life threatenin... |
DB00673 | DB08895 | 723 | 976 | [
"DDInter112",
"DDInter1825"
] | Aprepitant | Tofacitinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
723,
24,
976
]
],
[
[
723,
23,
307
],
[
307,
23,
976
]
],
[
[
723,
24,
214
],
[
214,
63,
976
]
],
[
[
723,
25,
982
],
[
982,
63,... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamati... |
DB00862 | DB11718 | 1,005 | 927 | [
"DDInter1918",
"DDInter640"
] | Vardenafil | Encorafenib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1005,
24,
927
]
],
[
[
1005,
24,
112
],
[
112,
23,
927
]
],
[
[
1005,
24,
720
],
[
720,
24,
927
]
],
[
[
1005,
63,
1010
],
[
1010,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00087 | DB10795 | 599 | 221 | [
"DDInter41",
"DDInter1486"
] | Alemtuzumab | Poliovirus type 1 antigen (formaldehyde inactivated) | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
599,
24,
221
]
],
[
[
599,
24,
36
],
[
36,
24,
221
]
],
[
[
599,
63,
581
],
[
581,
24,
221
]
],
[
[
599,
25,
1510
],
[
1510,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Alemtuzumab may cause a moderate interaction that could exacerbate diseas... |
DB00704 | DB06212 | 267 | 165 | [
"DDInter1263",
"DDInter1833"
] | Naltrexone | Tolvaptan | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
267,
24,
165
]
],
[
[
267,
63,
522
],
[
522,
1,
165
]
],
[
[
267,
6,
4973
],
[
4973,
45,
165
]
],
[
[
267,
21,
28789
],
[
28789,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) resembles Tolvaptan (Compound)
Naltrexone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tolvaptan (Compound)
Naltrexone (Compound) causes Loss of consciousness (Side Effect) and... |
DB08911 | DB12035 | 1,556 | 943 | [
"DDInter1842",
"DDInter1641"
] | Trametinib | Sarecycline | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1556,
24,
943
]
],
[
[
1556,
24,
384
],
[
384,
24,
943
]
],
[
[
1556,
24,
971
],
[
971,
63,
943
]
],
[
[
1556,
24,
384
],
[
384,
... | [
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gil... |
DB06168 | DB09074 | 1,531 | 1,362 | [
"DDInter281",
"DDInter1327"
] | Canakinumab | Olaparib | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1531,
24,
1362
]
],
[
[
1531,
25,
725
],
[
725,
63,
1362
]
],
[
[
1531,
63,
896
],
[
896,
24,
1362
]
],
[
[
1531,
24,
250
],
[
250,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satraliz... | Canakinumab may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may caus... |
DB00490 | DB11718 | 946 | 927 | [
"DDInter254",
"DDInter640"
] | Buspirone | Encorafenib | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
946,
24,
927
]
],
[
[
946,
63,
1324
],
[
1324,
24,
927
]
],
[
[
946,
25,
1264
],
[
1264,
24,
927
]
],
[
[
946,
24,
770
],
[
770,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Buspirone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a m... |
DB00010 | DB06292 | 1,649 | 549 | [
"DDInter1661",
"DDInter474"
] | Sermorelin | Dapagliflozin | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1649,
24,
549
]
],
[
[
1649,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1649,
24,
1179
],
[
1179,
24,
549
]
],
[
[
1649,
24,
1296
],
[
1296,... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate inter... |
DB00520 | DB00704 | 1,358 | 267 | [
"DDInter306",
"DDInter1263"
] | Caspofungin | Naltrexone | Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of th... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1358,
24,
267
]
],
[
[
1358,
6,
4973
],
[
4973,
45,
267
]
],
[
[
1358,
21,
28695
],
[
28695,
60,
267
]
],
[
[
1358,
24,
850
],
[
850,
... | [
[
[
"Caspofungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Caspofungin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Caspofungin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Caspofungin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin ... |
DB01067 | DB08815 | 959 | 154 | [
"DDInter826",
"DDInter1104"
] | Glipizide | Lurasidone | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
959,
24,
154
]
],
[
[
959,
6,
8374
],
[
8374,
45,
154
]
],
[
[
959,
21,
29402
],
[
29402,
60,
154
]
],
[
[
959,
24,
1033
],
[
1033,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Glipizide (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB09054 | DB12010 | 384 | 214 | [
"DDInter905",
"DDInter785"
] | Idelalisib | Fostamatinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
384,
25,
214
]
],
[
[
384,
64,
976
],
[
976,
24,
214
]
],
[
[
384,
63,
1428
],
[
1428,
24,
214
]
],
[
[
384,
25,
861
],
[
861,
6... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{... | Idelalisib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may ca... |
DB12267 | DB14711 | 1,476 | 779 | [
"DDInter233",
"DDInter1680"
] | Brigatinib | Smallpox (Vaccinia) Vaccine, Live | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1476,
25,
779
]
],
[
[
1476,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1476,
63,
478
],
[
478,
25,
779
]
],
[
[
1476,
62,
168
],
[
168,
... | [
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cl... | Brigatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may ... |
DB01191 | DB08881 | 1,039 | 868 | [
"DDInter518",
"DDInter1925"
] | Dexfenfluramine | Vemurafenib | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1039,
24,
868
]
],
[
[
1039,
6,
12523
],
[
12523,
45,
868
]
],
[
[
1039,
18,
2551
],
[
2551,
57,
868
]
],
[
[
1039,
62,
211
],
[
211,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (... | Dexfenfluramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Dexfenfluramine (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Vemurafenib (Compound)
Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine an... |
DB00065 | DB15965 | 581 | 1,330 | [
"DDInter923",
"DDInter1270"
] | Infliximab | Naxitamab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
581,
25,
1330
]
],
[
[
581,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
581,
25,
1532
],
[
1532,
24,
1330
]
],
[
[
581,
24,
14
],
[
14,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Infliximab may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cau... |
DB01128 | DB01229 | 918 | 973 | [
"DDInter204",
"DDInter1377"
] | Bicalutamide | Paclitaxel | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
918,
24,
973
]
],
[
[
918,
6,
8374
],
[
8374,
45,
973
]
],
[
[
918,
7,
17537
],
[
17537,
46,
973
]
],
[
[
918,
21,
29267
],
[
29267,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Bicalutamide (Compound) upregulates USP6NL (Gene) and USP6NL (Gene) is upregulated by Paclitaxel (Compound)
Bicalutamide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increas... |
DB00682 | DB01098 | 126 | 14 | [
"DDInter1951",
"DDInter1622"
] | Warfarin | Rosuvastatin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
126,
24,
14
]
],
[
[
126,
23,
671
],
[
671,
24,
14
]
],
[
[
126,
6,
8374
],
[
8374,
45,
14
]
],
[
[
126,
64,
600
],
[
600,
23,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvastatin"
],
[
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Warfarin may lead ... |
DB01169 | DB08865 | 57 | 1,593 | [
"DDInter120",
"DDInter448"
] | Arsenic trioxide | Crizotinib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
57,
25,
1593
]
],
[
[
57,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
57,
6,
3517
],
[
3517,
46,
1593
]
],
[
[
57,
6,
2084
],
[
2084,
5... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Arsenic trioxide (Compound) binds TXNRD1 (Gene) and TXNRD1 (Gene) is upregulated by Crizotinib (Compound)
Arsenic trioxide (Compound) binds AKT1 (Gene) and AKT1 (Gene) is downregulated by Crizotinib (Compound)
Arsenic tr... |
DB01128 | DB12245 | 918 | 823 | [
"DDInter204",
"DDInter1863"
] | Bicalutamide | Triclabendazole | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
918,
24,
823
]
],
[
[
918,
62,
1247
],
[
1247,
23,
823
]
],
[
[
918,
24,
1612
],
[
1612,
24,
823
]
],
[
[
918,
63,
1010
],
[
1010,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fost... |
DB01073 | DB10583 | 1,488 | 949 | [
"DDInter745",
"DDInter415"
] | Fludarabine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
1488,
24,
949
]
],
[
[
1488,
63,
589
],
[
589,
24,
949
]
],
[
[
1488,
25,
1377
],
[
1377,
24,
949
]
],
[
[
1488,
24,
980
],
[
980,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Fludarabine may lead to a major life threatening interaction wh... |
DB00367 | DB01067 | 566 | 959 | [
"DDInter1061",
"DDInter826"
] | Levonorgestrel | Glipizide | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
566,
24,
959
]
],
[
[
566,
63,
245
],
[
245,
40,
959
]
],
[
[
566,
24,
1411
],
[
1411,
1,
959
]
],
[
[
566,
6,
8374
],
[
8374,
4... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (... |
DB00470 | DB00964 | 530 | 1,617 | [
"DDInter601",
"DDInter110"
] | Dronabinol | Apraclonidine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
530,
24,
1617
]
],
[
[
530,
24,
1020
],
[
1020,
1,
1617
]
],
[
[
530,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
530,
21,
28975
],
[
28975,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apraclonidine (Compou... |
DB00262 | DB09074 | 552 | 1,362 | [
"DDInter302",
"DDInter1327"
] | Carmustine | Olaparib | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
552,
24,
1362
]
],
[
[
552,
24,
896
],
[
896,
24,
1362
]
],
[
[
552,
24,
385
],
[
385,
63,
1362
]
],
[
[
552,
63,
58
],
[
58,
24... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab... |
DB00176 | DB01234 | 529 | 1,220 | [
"DDInter770",
"DDInter513"
] | Fluvoxamine | Dexamethasone | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
529,
24,
1220
]
],
[
[
529,
24,
870
],
[
870,
1,
1220
]
],
[
[
529,
24,
175
],
[
175,
40,
1220
]
],
[
[
529,
6,
21998
],
[
21998,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles D... |
DB01246 | DB06176 | 820 | 1,342 | [
"DDInter45",
"DDInter1616"
] | Alimemazine | Romidepsin | A phenothiazine derivative that is used as an antipruritic. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
820,
24,
1342
]
],
[
[
820,
62,
1247
],
[
1247,
23,
1342
]
],
[
[
820,
63,
336
],
[
336,
24,
1342
]
],
[
[
820,
24,
1616
],
[
1616,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine ... |
DB04951 | DB09039 | 187 | 1,670 | [
"DDInter1477",
"DDInter629"
] | Pirfenidone | Eliglustat | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
187,
24,
1670
]
],
[
[
187,
63,
1288
],
[
1288,
24,
1670
]
],
[
[
187,
24,
655
],
[
655,
24,
1670
]
],
[
[
187,
25,
868
],
[
868,
... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
],
[
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Zileuton and Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etraviri... |
DB08901 | DB14443 | 1,468 | 987 | [
"DDInter1492",
"DDInter1931"
] | Ponatinib | Vibrio cholerae CVD 103-HgR strain live antigen | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1468,
24,
987
]
],
[
[
1468,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1468,
63,
1220
],
[
1220,
24,
987
]
],
[
[
1468,
64,
1172
],
[
1172,... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may cause a moderate interaction that could exacerbate diseases when t... |
DB00358 | DB11796 | 1,010 | 1,612 | [
"DDInter1140",
"DDInter786"
] | Mefloquine | Fostemsavir | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1010,
24,
1612
]
],
[
[
1010,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
1010,
24,
98
],
[
98,
23,
1612
]
],
[
[
1010,
24,
1476
],
[
1476,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem... |
DB00302 | DB00675 | 335 | 888 | [
"DDInter1844",
"DDInter1744"
] | Tranexamic acid | Tamoxifen | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Major | 2 | [
[
[
335,
25,
888
]
],
[
[
335,
21,
28701
],
[
28701,
60,
888
]
],
[
[
335,
25,
303
],
[
303,
23,
888
]
],
[
[
335,
25,
350
],
[
350,
... | [
[
[
"Tranexamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Tranexamic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused b... | Tranexamic acid (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Tamoxifen (Compound)
Tranexamic acid may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical eff... |
DB00290 | DB11601 | 329 | 1,270 | [
"DDInter219",
"DDInter1889"
] | Bleomycin | Tuberculin purified protein derivative | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
329,
24,
1270
]
],
[
[
329,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
329,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
329,
25,
850
],
[
850,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Bleomycin may lead to a major life threatening interaction when taken with Cladribi... |
DB00197 | DB00514 | 1,324 | 506 | [
"DDInter1881",
"DDInter527"
] | Troglitazone | Dextromethorphan | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
1324,
24,
506
]
],
[
[
1324,
24,
890
],
[
890,
40,
506
]
],
[
[
1324,
24,
741
],
[
741,
63,
506
]
],
[
[
1324,
24,
902
],
[
902,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Dextromethorphan (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction th... |
DB00938 | DB01072 | 455 | 915 | [
"DDInter1635",
"DDInter129"
] | Salmeterol | Atazanavir | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Major | 2 | [
[
[
455,
25,
915
]
],
[
[
455,
25,
1327
],
[
1327,
1,
915
]
],
[
[
455,
6,
8374
],
[
8374,
45,
915
]
],
[
[
455,
21,
29052
],
[
29052,
... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (... | Salmeterol may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound)
Salmeterol (Compound) causes Sleep disorder (Side Effect) and Sleep disorder (Sid... |
DB00013 | DB05578 | 1,255 | 330 | [
"DDInter1905",
"DDInter1566"
] | Urokinase | Ramucirumab | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
1255,
25,
330
]
],
[
[
1255,
24,
41
],
[
41,
63,
330
]
],
[
[
1255,
24,
901
],
[
901,
24,
330
]
],
[
[
1255,
24,
1317
],
[
1317,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomi... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran ... |
DB01211 | DB06016 | 609 | 1,508 | [
"DDInter393",
"DDInter300"
] | Clarithromycin | Cariprazine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Major | 2 | [
[
[
609,
25,
1508
]
],
[
[
609,
25,
1593
],
[
1593,
63,
1508
]
],
[
[
609,
62,
600
],
[
600,
24,
1508
]
],
[
[
609,
63,
176
],
[
176,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Clarithromycin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole m... |
DB01211 | DB09098 | 609 | 98 | [
"DDInter393",
"DDInter1700"
] | Clarithromycin | Somatrem | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
609,
24,
98
]
],
[
[
609,
24,
1612
],
[
1612,
62,
98
]
],
[
[
609,
63,
168
],
[
168,
23,
98
]
],
[
[
609,
23,
1459
],
[
1459,
23... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and ... |
DB00661 | DB12332 | 122 | 1,619 | [
"DDInter1928",
"DDInter1626"
] | Verapamil | Rucaparib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
122,
24,
1619
]
],
[
[
122,
23,
222
],
[
222,
23,
1619
]
],
[
[
122,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
122,
24,
309
],
[
309,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Verapamil may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Verapamil may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor... |
DB00446 | DB11730 | 597 | 351 | [
"DDInter351",
"DDInter1588"
] | Chloramphenicol | Ribociclib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
597,
24,
351
]
],
[
[
597,
23,
271
],
[
271,
23,
351
]
],
[
[
597,
23,
466
],
[
466,
62,
351
]
],
[
[
597,
24,
112
],
[
112,
23,... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
... | Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Darolutamide and ... |
DB06779 | DB10672 | 365 | 297 | [
"DDInter470",
"DDInter417"
] | Dalteparin | Clove | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
365,
23,
297
]
],
[
[
365,
25,
235
],
[
235,
62,
297
]
],
[
[
365,
25,
578
],
[
578,
23,
297
]
],
[
[
365,
64,
1564
],
[
1564,
2... | [
[
[
"Dalteparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
... | Dalteparin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Dalteparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interaction that... |
DB00604 | DB09065 | 1,425 | 760 | [
"DDInter385",
"DDInter424"
] | Cisapride | Cobicistat | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1425,
25,
760
]
],
[
[
1425,
24,
479
],
[
479,
23,
760
]
],
[
[
1425,
64,
1230
],
[
1230,
23,
760
]
],
[
[
1425,
63,
1101
],
[
1101,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cisapride may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a mino... |
DB00743 | DB01232 | 808 | 1,327 | [
"DDInter792",
"DDInter1640"
] | Gadobenic acid | Saquinavir | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
808,
24,
1327
]
],
[
[
808,
63,
798
],
[
798,
40,
1327
]
],
[
[
808,
24,
915
],
[
915,
40,
1327
]
],
[
[
808,
6,
1829
],
[
1829,
... | [
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
... | Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Co... |
DB00075 | DB11988 | 541 | 270 | [
"DDInter1250",
"DDInter1321"
] | Muromonab | Ocrelizumab | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
541,
24,
270
]
],
[
[
541,
23,
1193
],
[
1193,
23,
270
]
],
[
[
541,
24,
713
],
[
713,
24,
270
]
],
[
[
541,
24,
287
],
[
287,
6... | [
[
[
"Muromonab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate ... |
DB00865 | DB01105 | 939 | 222 | [
"DDInter187",
"DDInter1665"
] | Benzphetamine | Sibutramine | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
939,
25,
222
]
],
[
[
939,
5,
11585
],
[
11585,
44,
222
]
],
[
[
939,
6,
8374
],
[
8374,
45,
222
]
],
[
[
939,
54,
19177
],
[
19177,
... | [
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzphetamine",
"{u} (Compound) treats {v} (Disease)",
"obesity"
],
[
"obesity",
"{u} (Disease) is treated by {v} (Compound... | Benzphetamine (Compound) treats obesity (Disease) and obesity (Disease) is treated by Sibutramine (Compound)
Benzphetamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Benzphetamine (Compound) is included by Appetite Suppression (Pharmacologic Class) and Appetite Suppression (Phar... |
DB00497 | DB06691 | 828 | 849 | [
"DDInter1366",
"DDInter1155"
] | Oxycodone | Mepyramine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
828,
24,
849
]
],
[
[
828,
63,
1594
],
[
1594,
24,
849
]
],
[
[
828,
24,
272
],
[
272,
24,
849
]
],
[
[
828,
6,
12523
],
[
12523,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Ch... |
DB00204 | DB06595 | 228 | 1,491 | [
"DDInter580",
"DDInter1214"
] | Dofetilide | Midostaurin | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
228,
25,
1491
]
],
[
[
228,
23,
112
],
[
112,
23,
1491
]
],
[
[
228,
25,
888
],
[
888,
24,
1491
]
],
[
[
228,
24,
1017
],
[
1017,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Dofetilide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause... |
DB00033 | DB09268 | 342 | 1,662 | [
"DDInter949",
"DDInter1464"
] | Interferon gamma-1b | Picosulfuric acid | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence ... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
342,
24,
1662
]
],
[
[
342,
24,
597
],
[
597,
24,
1662
]
],
[
[
342,
25,
593
],
[
593,
24,
1662
]
],
[
[
342,
24,
597
],
[
597,
... | [
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ch... | Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Interferon gamma-1b may lead to a major life threatening interaction when taken with B... |
DB00685 | DB01309 | 1,299 | 1,254 | [
"DDInter1887",
"DDInter933"
] | Trovafloxacin | Insulin glulisine | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Major | 2 | [
[
[
1299,
25,
1254
]
],
[
[
1299,
25,
167
],
[
167,
24,
1254
]
],
[
[
1299,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
1299,
24,
170
],
[
170,
... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocor... | Trovafloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and M... |
DB01181 | DB01618 | 1,532 | 776 | [
"DDInter906",
"DDInter1239"
] | Ifosfamide | Molindone | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1532,
24,
776
]
],
[
[
1532,
18,
17480
],
[
17480,
57,
776
]
],
[
[
1532,
21,
28800
],
[
28800,
60,
776
]
],
[
[
1532,
63,
100
],
[
10... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Ifosfamide",
"{u} (Compound) downregulates {v} (Gene)",
"ENOPH1"
],
[
"ENOPH1",
"{u} (Gene) is downregulated by {... | Ifosfamide (Compound) downregulates ENOPH1 (Gene) and ENOPH1 (Gene) is downregulated by Molindone (Compound)
Ifosfamide (Compound) causes Dyskinesia (Side Effect) and Dyskinesia (Side Effect) is caused by Molindone (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Bro... |
DB00363 | DB11827 | 695 | 433 | [
"DDInter419",
"DDInter669"
] | Clozapine | Ertugliflozin | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
695,
24,
433
]
],
[
[
695,
24,
959
],
[
959,
24,
433
]
],
[
[
695,
64,
521
],
[
521,
24,
433
]
],
[
[
695,
40,
867
],
[
867,
24,... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Clozapine may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a m... |
DB09054 | DB14568 | 384 | 982 | [
"DDInter905",
"DDInter1000"
] | Idelalisib | Ivosidenib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
384,
25,
982
]
],
[
[
384,
62,
271
],
[
271,
23,
982
]
],
[
[
384,
63,
168
],
[
168,
23,
982
]
],
[
[
384,
64,
976
],
[
976,
24,... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",... | Idelalisib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib... |
DB00978 | DB11978 | 739 | 124 | [
"DDInter1084",
"DDInter822"
] | Lomefloxacin | Glasdegib | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
739,
24,
124
]
],
[
[
739,
62,
112
],
[
112,
23,
124
]
],
[
[
739,
63,
79
],
[
79,
24,
124
]
],
[
[
739,
24,
688
],
[
688,
24,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and So... |
DB00213 | DB01066 | 837 | 1,462 | [
"DDInter1388",
"DDInter316"
] | Pantoprazole | Cefditoren | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
837,
24,
1462
]
],
[
[
837,
24,
665
],
[
665,
40,
1462
]
],
[
[
837,
1,
660
],
[
660,
24,
1462
]
],
[
[
837,
24,
126
],
[
126,
2... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefditoren (Compound)
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cef... |
DB00556 | DB00581 | 1,262 | 355 | [
"DDInter1429",
"DDInter1018"
] | Perflutren | Lactulose | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
1262,
24,
355
]
],
[
[
1262,
21,
28722
],
[
28722,
60,
355
]
],
[
[
1262,
24,
286
],
[
286,
62,
355
]
],
[
[
1262,
63,
79
],
[
79,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Perflutren (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lactulose (Compound)
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken wit... |
DB00620 | DB11057 | 175 | 720 | [
"DDInter1855",
"DDInter1223"
] | Triamcinolone | Mineral oil | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
175,
24,
720
]
],
[
[
175,
63,
323
],
[
323,
24,
720
]
],
[
[
175,
40,
1486
],
[
1486,
24,
720
]
],
[
[
175,
25,
609
],
[
609,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Triamcinolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone ma... |
DB00635 | DB00939 | 1,573 | 1,338 | [
"DDInter1515",
"DDInter1135"
] | Prednisone | Meclofenamic acid | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1573,
24,
1338
]
],
[
[
1573,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1573,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
1573,
1,
1486
],
[
1... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Prednisone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Ef... |
DB00560 | DB01024 | 753 | 1,096 | [
"DDInter1805",
"DDInter1252"
] | Tigecycline | Mycophenolic acid | Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17,... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
753,
24,
1096
]
],
[
[
753,
40,
964
],
[
964,
24,
1096
]
],
[
[
753,
1,
1545
],
[
1545,
24,
1096
]
],
[
[
753,
40,
964
],
[
964,
... | [
[
[
"Tigecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Tigecycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may caus... | Tigecycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Tigecycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when t... |
DB00476 | DB00857 | 109 | 1,387 | [
"DDInter608",
"DDInter1768"
] | Duloxetine | Terbinafine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
109,
24,
1387
]
],
[
[
109,
40,
11498
],
[
11498,
40,
1387
]
],
[
[
109,
40,
11325
],
[
11325,
1,
1387
]
],
[
[
109,
6,
12523
],
[
125... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Duloxetine",
"{u} (Compound) resembles {v} (Compound)",
"Naphazoline"
],
[
"Naphazoline",
"{u} (Compound) resem... | Duloxetine (Compound) resembles Naphazoline (Compound) and Naphazoline (Compound) resembles Terbinafine (Compound)
Duloxetine (Compound) resembles Butenafine (Compound) and Butenafine (Compound) resembles Terbinafine (Compound)
Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Terbinafine (Compoun... |
DB00095 | DB00635 | 66 | 1,573 | [
"DDInter623",
"DDInter1515"
] | Efalizumab | Prednisone | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
66,
24,
1573
]
],
[
[
66,
24,
175
],
[
175,
40,
1573
]
],
[
[
66,
24,
251
],
[
251,
1,
1573
]
],
[
[
66,
23,
1461
],
[
1461,
23,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone... |
DB00959 | DB01041 | 1,486 | 770 | [
"DDInter1191",
"DDInter1789"
] | Methylprednisolone | Thalidomide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1486,
25,
770
]
],
[
[
1486,
10,
11555
],
[
11555,
44,
770
]
],
[
[
1486,
7,
3823
],
[
3823,
46,
770
]
],
[
[
1486,
18,
20113
],
[
201... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) palliates {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (D... | Methylprednisolone (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Thalidomide (Compound)
Methylprednisolone (Compound) upregulates FKBP5 (Gene) and FKBP5 (Gene) is upregulated by Thalidomide (Compound)
Methylprednisolone (Compound) downregulates IER3 (Gene) and IER3 (Ge... |
DB01058 | DB12301 | 978 | 907 | [
"DDInter1510",
"DDInter585"
] | Praziquantel | Doravirine | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Moderate | 1 | [
[
[
978,
24,
907
]
],
[
[
978,
24,
159
],
[
159,
62,
907
]
],
[
[
978,
24,
351
],
[
351,
23,
907
]
],
[
[
978,
62,
752
],
[
752,
23,... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib an... |
DB00294 | DB01276 | 1,336 | 123 | [
"DDInter701",
"DDInter706"
] | Etonogestrel | Exenatide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1336,
24,
123
]
],
[
[
1336,
40,
984
],
[
984,
63,
123
]
],
[
[
1336,
25,
1476
],
[
1476,
63,
123
]
],
[
[
1336,
63,
1685
],
[
1685,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Etonogestrel",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate i... | Etonogestrel (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Etonogestrel may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseas... |
DB08904 | DB08908 | 375 | 713 | [
"DDInter342",
"DDInter564"
] | Certolizumab pegol | Dimethyl fumarate | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Major | 2 | [
[
[
375,
25,
713
]
],
[
[
375,
64,
1083
],
[
1083,
24,
713
]
],
[
[
375,
25,
725
],
[
725,
63,
713
]
],
[
[
375,
24,
221
],
[
221,
6... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"... | Certolizumab pegol may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Certolizumab pegol may lead to a major life threatening interaction when taken with Satralizumab and Satrali... |
DB00196 | DB04844 | 600 | 843 | [
"DDInter743",
"DDInter1778"
] | Fluconazole | Tetrabenazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
600,
24,
843
]
],
[
[
600,
23,
479
],
[
479,
40,
843
]
],
[
[
600,
21,
28698
],
[
28698,
60,
843
]
],
[
[
600,
23,
112
],
[
112,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Fluconazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Fluconazole may cause a minor interaction ... |
DB00363 | DB06788 | 695 | 1,616 | [
"DDInter419",
"DDInter864"
] | Clozapine | Histrelin | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
695,
25,
1616
]
],
[
[
695,
23,
112
],
[
112,
23,
1616
]
],
[
[
695,
1,
623
],
[
623,
24,
1616
]
],
[
[
695,
25,
1342
],
[
1342,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Clozapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could ... |
DB00196 | DB11799 | 600 | 627 | [
"DDInter743",
"DDInter205"
] | Fluconazole | Bictegravir | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
600,
24,
627
]
],
[
[
600,
25,
1362
],
[
1362,
24,
627
]
],
[
[
600,
24,
578
],
[
578,
24,
627
]
],
[
[
600,
23,
466
],
[
466,
6... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib"... | Fluconazole may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a... |
DB00191 | DB09045 | 73 | 52 | [
"DDInter1447",
"DDInter607"
] | Phentermine | Dulaglutide | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
73,
24,
52
]
],
[
[
73,
24,
170
],
[
170,
23,
52
]
],
[
[
73,
35,
280
],
[
280,
24,
52
]
],
[
[
73,
24,
532
],
[
532,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Phentermine (Compound) resembles Mephentermine (Compound) and Phentermine may cause a moderate interaction tha... |
DB00065 | DB09121 | 581 | 1,328 | [
"DDInter923",
"DDInter140"
] | Infliximab | Aurothioglucose | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
581,
24,
1328
]
],
[
[
581,
24,
367
],
[
367,
24,
1328
]
],
[
[
581,
63,
268
],
[
268,
24,
1328
]
],
[
[
581,
25,
310
],
[
310,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Infliximab may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00539 | DB00581 | 11 | 355 | [
"DDInter1837",
"DDInter1018"
] | Toremifene | Lactulose | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
11,
24,
355
]
],
[
[
11,
21,
28722
],
[
28722,
60,
355
]
],
[
[
11,
24,
286
],
[
286,
62,
355
]
],
[
[
11,
25,
1262
],
[
1262,
2... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Toremifene (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lactulose (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken wit... |
DB00262 | DB01174 | 552 | 697 | [
"DDInter302",
"DDInter1442"
] | Carmustine | Phenobarbital | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
552,
24,
697
]
],
[
[
552,
63,
362
],
[
362,
1,
697
]
],
[
[
552,
24,
157
],
[
157,
1,
697
]
],
[
[
552,
6,
7950
],
[
7950,
45,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Phenobarbital (Compound)
... |
DB00280 | DB06273 | 494 | 980 | [
"DDInter575",
"DDInter1824"
] | Disopyramide | Tocilizumab | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
494,
24,
980
]
],
[
[
494,
63,
1031
],
[
1031,
24,
980
]
],
[
[
494,
25,
1487
],
[
1487,
24,
980
]
],
[
[
494,
24,
629
],
[
629,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Disopyramide may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydr... |
DB00095 | DB13985 | 66 | 546 | [
"DDInter623",
"DDInter1108"
] | Efalizumab | Lutetium Lu 177 dotatate | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
66,
24,
546
]
],
[
[
66,
24,
1683
],
[
1683,
24,
546
]
],
[
[
66,
63,
58
],
[
58,
24,
546
]
],
[
[
66,
63,
1057
],
[
1057,
25,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefa... |
DB00834 | DB06441 | 932 | 936 | [
"DDInter1215",
"DDInter283"
] | Mifepristone | Cangrelor | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
932,
25,
936
]
],
[
[
932,
25,
477
],
[
477,
24,
936
]
],
[
[
932,
24,
848
],
[
848,
24,
936
]
],
[
[
932,
63,
1512
],
[
1512,
2... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u... | Mifepristone may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause... |
DB01001 | DB04948 | 688 | 1,084 | [
"DDInter1632",
"DDInter1083"
] | Salbutamol | Lofexidine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
688,
24,
1084
]
],
[
[
688,
62,
112
],
[
112,
23,
1084
]
],
[
[
688,
63,
618
],
[
618,
24,
1084
]
],
[
[
688,
24,
774
],
[
774,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarel... |
DB01344 | DB13749 | 1,231 | 1,473 | [
"DDInter1830",
"DDInter1116"
] | Tolevamer | Magnesium gluconate | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
1231,
24,
1473
]
],
[
[
1231,
63,
544
],
[
544,
24,
1473
]
],
[
[
1231,
24,
853
],
[
853,
24,
1473
]
],
[
[
1231,
63,
544
],
[
544,
... | [
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
... | Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.